What Researchers Discovered

Mayo Clinic researchers have identified a crucial mechanism by⁤ which excessive alcohol consumption⁤ contributes to fatty⁢ liver disease, formally known as Metabolic Dysfunction Associated Steatotic Liver‍ Disease (MASLD). MASLD affects over one-third of⁤ peopel in⁤ the U.S. and can progress to‍ serious conditions⁣ like type 2 diabetes⁤ and liver cancer. The study, ⁣published recently, reveals how alcohol impacts ‍a specific cellular ⁢process, possibly ⁤opening avenues for new treatments.

The research centers on ⁣the protein HSD17β13 and its relationship with lipid⁤ droplets – fat storage units within liver cells. Researchers found that exposure to excessive alcohol alters the function of VCP, a protein that normally directs HSD17β13 from lipid droplets to ⁢lysosomes, cellular structures responsible ⁢for breaking down fats.When VCP is disrupted, HSD17β13 remains stuck in the lipid droplets, hindering the liver’s ability to reduce fat ⁢accumulation.

“We were seeing, and every result indicated VCP directs ‍the HSD17β13 protein from the ⁣lipid droplet to the lysosome,” says Sandhya Sen, Ph.D., a mayo⁣ Clinic research fellow⁢ and lead author of the study. This ⁤finding establishes ⁢HSD17β13 ⁤as ⁤a potential therapeutic target.

Implications for Treatment and Prevention

the discovery that HSD17β13 is⁣ a key player in fat metabolism within the liver has notable implications for developing new therapies. ⁢ Dr. McNiven suggests that targeting this protein could ‍offer a way to prevent⁢ or treat MASLD.

“This study increases our understanding ⁢of the biology of lipid droplets, the central culprit of fatty liver, and how the hepatocyte works in ‍an effort to reduce its fat content,” says Dr. McNiven. “It also could help predict which patients ‍are ⁢prone to the detrimental effect ⁣of excessive alcohol consumption on their ‍liver if this cellular system is compromised.”

Beyond alcohol-related liver⁢ disease, the findings could also be relevant to understanding and⁢ treating MASLD caused⁤ by other factors, such as obesity and diabetes. The disruption of ⁢the VCP-HSD17β13 pathway may be ⁢a common thread in various forms of fatty liver disease.

The Precure Initiative

This research is part of the Mayo Clinic’s larger Precure initiative, a program focused on⁢ developing tools to predict and intercept biological processes before they develop into full-blown diseases. The initiative aims to move beyond‍ treating illness to proactively preventing it.

The precure initiative leverages advanced technologies and ⁢collaborative research to identify biomarkers and ⁢therapeutic targets for a range of ⁤conditions, including cardiovascular disease, cancer, and neurodegenerative disorders.